ENTX

Entera Bio Ltd.

2.11 USD
+0.05 (+2.43%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Entera Bio Ltd. stock is down -11.34% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 6 June’s closed higher than May. 100% of analysts rate it a buy.

About Entera Bio Ltd.

Entera Bio Ltd. focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism.